JP2020011980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020011980A5 JP2020011980A5 JP2019172295A JP2019172295A JP2020011980A5 JP 2020011980 A5 JP2020011980 A5 JP 2020011980A5 JP 2019172295 A JP2019172295 A JP 2019172295A JP 2019172295 A JP2019172295 A JP 2019172295A JP 2020011980 A5 JP2020011980 A5 JP 2020011980A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021152652A JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26114909P | 2009-11-13 | 2009-11-13 | |
| US61/261,149 | 2009-11-13 | ||
| JP2017206911A JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206911A Division JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152652A Division JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020011980A JP2020011980A (ja) | 2020-01-23 |
| JP2020011980A5 true JP2020011980A5 (enExample) | 2020-04-16 |
| JP7317650B2 JP7317650B2 (ja) | 2023-07-31 |
Family
ID=43618172
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538994A Active JP5931736B2 (ja) | 2009-11-13 | 2010-11-12 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2019172295A Active JP7317650B2 (ja) | 2009-11-13 | 2019-09-20 | Ｈｅｒ－３関連疾患を治療または予防するための物質および方法 |
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538994A Active JP5931736B2 (ja) | 2009-11-13 | 2010-11-12 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9101760B2 (enExample) |
| EP (5) | EP3670539A1 (enExample) |
| JP (5) | JP5931736B2 (enExample) |
| KR (1) | KR101806323B1 (enExample) |
| CN (2) | CN105999263B (enExample) |
| AR (1) | AR080564A1 (enExample) |
| AU (1) | AU2010319483B2 (enExample) |
| BR (1) | BR112012012160B1 (enExample) |
| CA (1) | CA2780935C (enExample) |
| CY (2) | CY1119751T1 (enExample) |
| DK (2) | DK2719708T3 (enExample) |
| ES (3) | ES2781299T3 (enExample) |
| HK (1) | HK1207651A1 (enExample) |
| HR (2) | HRP20180104T1 (enExample) |
| HU (2) | HUE049880T2 (enExample) |
| LT (2) | LT2719708T (enExample) |
| MX (3) | MX349513B (enExample) |
| NO (1) | NO2719708T3 (enExample) |
| PL (2) | PL3351558T3 (enExample) |
| PT (2) | PT3351558T (enExample) |
| RS (2) | RS56741B1 (enExample) |
| SI (2) | SI3351558T1 (enExample) |
| SM (2) | SMT202000267T1 (enExample) |
| TW (1) | TWI630916B (enExample) |
| UY (1) | UY33034A (enExample) |
| WO (1) | WO2011060206A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| EP3488866A1 (en) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| KR20150036824A (ko) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| US9139825B2 (en) | 2009-10-30 | 2015-09-22 | Novartis Ag | Universal fibronectin type III bottom-side binding domain libraries |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| AU2011283646B2 (en) | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012059857A2 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Pan-her antibody composition |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| WO2013048883A2 (en) | 2011-09-30 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| CN108424456B (zh) | 2011-11-23 | 2022-04-26 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
| CN108341873B (zh) * | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| EP2788381A2 (en) * | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
| US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| CN104136464A (zh) * | 2012-02-23 | 2014-11-05 | U3制药有限公司 | 用于调节放射敏感性的her3抑制剂 |
| HK1202431A1 (en) * | 2012-05-02 | 2015-10-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| US20160106856A1 (en) * | 2012-08-14 | 2016-04-21 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
| EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| CA2891190C (en) * | 2012-11-12 | 2021-08-31 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US12685781B2 (en) | 2014-04-10 | 2026-07-21 | Daiichi Sankyo Company, Limited | Anti-HER3 antibody-drug conjugate |
| TWI871999B (zh) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| CN104861068B (zh) * | 2015-01-23 | 2020-11-17 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗her3抗体及其治疗相关疾病的用途 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
| KR102469700B1 (ko) * | 2016-09-15 | 2022-11-23 | 우니베르지테트 스튜트가르트 | Her3에 대한 항원 결합 단백질 |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| EP3615067A1 (en) | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
| WO2019241893A2 (en) * | 2018-06-22 | 2019-12-26 | Crd Pharmaceuticals Inc | Anti-her3 antibody and uses thereof |
| EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
| IL325918A (en) | 2018-07-31 | 2026-03-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates for use in the treatment of metastatic brain tumor |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2021154746A1 (en) | 2020-01-28 | 2021-08-05 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
| US20260028417A1 (en) * | 2022-03-03 | 2026-01-29 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Her3 binding protein and use thereof |
| WO2023208216A1 (en) * | 2022-04-29 | 2023-11-02 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugates and preparation methods and use thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4471052A (en) | 1982-01-18 | 1984-09-11 | Adria Laboratories, Inc. | Biosynthesis of simplified anthracyclines |
| JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US4939168A (en) | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| CA2175893C (en) | 1993-11-23 | 2010-06-22 | Paul J. Godowski | Protein tyrosine kinases named rse |
| FR2718135B1 (fr) | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
| FR2721928A1 (fr) | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
| EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
| US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| DK0896586T4 (en) | 1996-03-27 | 2015-08-24 | Genentech Inc | ErbB3 antibodies. |
| US6114595A (en) | 1996-04-11 | 2000-09-05 | The Procter & Gamble Company | Stretchable, extensible composite topsheet for absorbent articles |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| JP2001505779A (ja) | 1996-12-11 | 2001-05-08 | スージェン・インコーポレーテッド | Ｐｙｋ２関連産物および方法 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN100381566C (zh) | 1998-11-20 | 2008-04-16 | 科森生物科学公司 | 产生环氧噻酮及其衍生物的重组方法和材料 |
| AU2209899A (en) | 1998-12-30 | 2000-07-24 | Sugen, Inc. | Pyk2 (raftk) and inflammation |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| FR2817258B1 (fr) | 2000-11-27 | 2003-01-10 | Atofina | Procede de sulfochloration photochimique d'alcanes gazeux |
| IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| DE60233744D1 (de) | 2001-09-20 | 2009-10-29 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests |
| ES2645563T3 (es) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| WO2003048730A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Identification of high affinity molecules by limited dilution screening |
| CN1219882C (zh) | 2002-03-18 | 2005-09-21 | 上海泽生科技开发有限公司 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
| CA2480099C (en) | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| ATE442589T1 (de) | 2002-07-25 | 2009-09-15 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| EP3698807A1 (en) * | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| MX2007010113A (es) | 2005-02-18 | 2007-12-07 | Angiochem Inc | Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica. |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| CN101351563A (zh) * | 2005-10-05 | 2009-01-21 | 阿斯利康(英国)有限公司 | 用于预测或监测病人对于ErbB受体药物的响应的方法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| AU2010284018C1 (en) * | 2009-08-21 | 2015-10-15 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of ErbB3 and uses thereof |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
-
2010
- 2010-11-12 KR KR1020127015255A patent/KR101806323B1/ko active Active
- 2010-11-12 TW TW099139038A patent/TWI630916B/zh active
- 2010-11-12 SM SM20200267T patent/SMT202000267T1/it unknown
- 2010-11-12 LT LTEP13189092.3T patent/LT2719708T/lt unknown
- 2010-11-12 MX MX2012005589A patent/MX349513B/es active IP Right Grant
- 2010-11-12 HU HUE17197711A patent/HUE049880T2/hu unknown
- 2010-11-12 MX MX2016008205A patent/MX358013B/es unknown
- 2010-11-12 ES ES17197711T patent/ES2781299T3/es active Active
- 2010-11-12 EP EP20151640.8A patent/EP3670539A1/en active Pending
- 2010-11-12 PT PT171977119T patent/PT3351558T/pt unknown
- 2010-11-12 PL PL17197711T patent/PL3351558T3/pl unknown
- 2010-11-12 NO NO13189092A patent/NO2719708T3/no unknown
- 2010-11-12 CN CN201610373755.5A patent/CN105999263B/zh active Active
- 2010-11-12 SI SI201032011T patent/SI3351558T1/sl unknown
- 2010-11-12 SM SM20180167T patent/SMT201800167T1/it unknown
- 2010-11-12 HU HUE13189092A patent/HUE035605T2/en unknown
- 2010-11-12 JP JP2012538994A patent/JP5931736B2/ja active Active
- 2010-11-12 US US12/944,764 patent/US9101760B2/en active Active
- 2010-11-12 AU AU2010319483A patent/AU2010319483B2/en active Active
- 2010-11-12 RS RS20180048A patent/RS56741B1/sr unknown
- 2010-11-12 DK DK13189092.3T patent/DK2719708T3/da active
- 2010-11-12 CA CA2780935A patent/CA2780935C/en active Active
- 2010-11-12 EP EP17197711.9A patent/EP3351558B1/en active Active
- 2010-11-12 SI SI201031627T patent/SI2719708T1/en unknown
- 2010-11-12 ES ES15154165.3T patent/ES2647466T3/es active Active
- 2010-11-12 PT PT131890923T patent/PT2719708T/pt unknown
- 2010-11-12 WO PCT/US2010/056430 patent/WO2011060206A2/en not_active Ceased
- 2010-11-12 BR BR112012012160-0A patent/BR112012012160B1/pt active IP Right Grant
- 2010-11-12 DK DK17197711.9T patent/DK3351558T3/da active
- 2010-11-12 EP EP15154165.3A patent/EP2896632B1/en active Active
- 2010-11-12 ES ES13189092.3T patent/ES2655737T3/es active Active
- 2010-11-12 EP EP10785251A patent/EP2499162A2/en not_active Withdrawn
- 2010-11-12 RS RS20200651A patent/RS60390B1/sr unknown
- 2010-11-12 LT LTEP17197711.9T patent/LT3351558T/lt unknown
- 2010-11-12 EP EP13189092.3A patent/EP2719708B1/en active Active
- 2010-11-12 CN CN201080052236.XA patent/CN102812045B/zh active Active
- 2010-11-12 PL PL13189092T patent/PL2719708T3/pl unknown
- 2010-11-12 MX MX2016002120A patent/MX357972B/es unknown
- 2010-11-15 UY UY33034A patent/UY33034A/es not_active Application Discontinuation
- 2010-11-15 AR ARP100104211 patent/AR080564A1/es unknown
-
2013
- 2013-04-25 US US13/870,796 patent/US9803025B2/en active Active
-
2015
- 2015-08-20 HK HK15108089.8A patent/HK1207651A1/en unknown
-
2016
- 2016-01-05 JP JP2016000552A patent/JP6235620B2/ja active Active
- 2016-01-18 US US15/000,005 patent/US9988462B2/en active Active
-
2017
- 2017-10-26 JP JP2017206911A patent/JP2018076300A/ja active Pending
- 2017-10-27 US US15/796,361 patent/US12139549B2/en active Active
- 2017-12-13 CY CY20171101305T patent/CY1119751T1/el unknown
-
2018
- 2018-01-19 HR HRP20180104TT patent/HRP20180104T1/hr unknown
-
2019
- 2019-09-20 JP JP2019172295A patent/JP7317650B2/ja active Active
-
2020
- 2020-06-05 CY CY20201100505T patent/CY1123030T1/el unknown
- 2020-06-08 HR HRP20200921TT patent/HRP20200921T1/hr unknown
-
2021
- 2021-09-17 JP JP2021152652A patent/JP2022000445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
| JP2013510868A5 (enExample) | ||
| JP2018508512A5 (enExample) | ||
| Ballantyne et al. | Trastuzumab emtansine: first global approval | |
| RU2010135585A (ru) | Моноклональные антитела для лечения опухолей | |
| JP2011512332A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2008531576A5 (enExample) | ||
| JP2016520082A5 (enExample) | ||
| JP2020055853A5 (enExample) | ||
| JP2022058802A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2008503476A5 (enExample) | ||
| JP2022058676A (ja) | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 | |
| JP2012509889A5 (enExample) | ||
| FI3223848T3 (fi) | Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model | |
| JP2023512196A5 (enExample) | ||
| MX2024014345A (es) | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos | |
| Khayat et al. | Taxol in the management of cancers of the breast and the ovary | |
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| JP2022512851A5 (enExample) | ||
| JP2025507817A5 (enExample) |